KRAS is a commonly mutated oncogene in CRC, occurring in approximately 40% of CRC cases; its mutation leads to constitutive activation of KRAS protein, which acts as a molecular switch to continuously stimulate downstream signaling pathways, including cell proliferation and survival, leading to tumorigenesis (136, 137). This evidence concerns the gene KRAS and colorectal carcinoma.